Wealthspire Advisors LLC Has $377,000 Stock Position in STERIS plc $STE

Wealthspire Advisors LLC raised its stake in STERIS plc (NYSE:STE) by 31.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,571 shares of the medical equipment provider’s stock after acquiring an additional 373 shares during the quarter. Wealthspire Advisors LLC’s holdings in STERIS were worth $377,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Spurstone Advisory Services LLC bought a new position in shares of STERIS during the second quarter worth approximately $29,000. Geneos Wealth Management Inc. grew its holdings in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in STERIS during the 1st quarter worth $37,000. Costello Asset Management INC acquired a new stake in shares of STERIS during the first quarter worth $45,000. Finally, Generali Investments Management Co LLC acquired a new stake in shares of STERIS during the second quarter worth $56,000. Institutional investors own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on STE shares. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, Morgan Stanley raised their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $273.50.

STERIS Trading Up 2.5%

Shares of STERIS stock opened at $263.34 on Friday. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. STERIS plc has a 12-month low of $200.98 and a 12-month high of $268.30. The company has a market capitalization of $25.85 billion, a price-to-earnings ratio of 40.33 and a beta of 1.02. The firm’s 50-day moving average price is $246.90 and its two-hundred day moving average price is $241.55.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. During the same quarter in the prior year, the firm posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be paid a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s dividend payout ratio (DPR) is presently 36.21%.

Insider Transactions at STERIS

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This trade represents a 46.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 20,195 shares of company stock valued at $5,312,571. Corporate insiders own 1.07% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.